An internal standard for the quantification of tolcapone
Related Products
Unlabeled Version(s)
20768Tolcapone
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Tolcapone-d4

Item No. 28697

Technical Information
Formal Name
(3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl-2,3,5,6-d4)methanone
CAS Number
1246816-93-2
Molecular Formula
C14H7D4NO5
Formula Weight
Purity
≥99% deuterated forms (d1-d4)
Formulation
A solid
DMSO: slightly solubleMethanol: slightly soluble
SMILES
CC1=C([2H])C([2H])=C(C(C2=CC([N+]([O-])=O)=C(O)C(O)=C2)=O)C([2H])=C1[2H]
InChi Code
InChI=1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3/i2D,3D,4D,5D
InChi Key
MIQPIUSUKVNLNT-QFFDRWTDSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Product Description

    Tolcapone-d4 is intended for use as an internal standard for the quantification of tolcapone (Item No. 20768) by GC- or LC-MS. Tolcapone is a reversible inhibitor of catechol-O-methyltransferase (COMT; Ki = 0.27 nM for human recombinant COMT), an enzyme that degrades catecholamines, including dopamine (Item No. 21992) and L-DOPA (Item No. 13248).1,2 Tolcapone crosses the blood brain barrier and can inhibit both peripheral and central COMT activity.3,4 By inhibiting COMT, tolcapone increases L-DOPA efficacy and reduces L-DOPA-induced motor complications in animal models of Parkinson’s disease.3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Lotta, T., Vidgren, J., Tilgmann, C., et alKinetics of human soluble and membrane-bound catechol O-methyltransferase: A revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 34(13), 4202-4210 (1995).

    2. Männistö, P.T., and Kaakkola, S. Catechol-O-methyltransferase (COMT): Biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol. Rev. 51(4), 593-628 (1999).

    3. Espinoza, S., Managó, F., Leo, D., et alRole of catechol-O-methyltransferase (COMT)-dependent processes in Parkinson’s disease and L-DOPA treatment. CNS Neurol. Disord. Drug Targets 11(3), 251-263 (2012).

    4. Männistö, P.T., Tuomainen, P., and Tuominen, R.K. Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat. Br. J. Pharmacol. 105(3), 569-574 (1992).